Identifying COVID-19 optimal vaccine dose using mathematical immunostimulation/immunodynamic modelling
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Identifying COVID-19 optimal vaccine dose using mathematical immunostimulation/immunodynamic modelling
Authors
Keywords
-
Journal
VACCINE
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-10-17
DOI
10.1016/j.vaccine.2022.10.012
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Could computer models be the key to better COVID vaccines?
- (2022) Elie Dolgin NATURE
- Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval
- (2021) Ebenezer Tumban Viruses-Basel
- Current and prospective computational approaches and challenges for developing COVID-19 vaccines
- (2021) Woochang Hwang et al. ADVANCED DRUG DELIVERY REVIEWS
- Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial
- (2021) Peter Richmond et al. LANCET
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2021) Zhiwei Wu et al. LANCET INFECTIOUS DISEASES
- Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials
- (2021) Shilong Yang et al. LANCET INFECTIOUS DISEASES
- Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial
- (2021) Keith J Chappell et al. LANCET INFECTIOUS DISEASES
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18–59 years: A phase I randomized, double-blinded, controlled trial
- (2021) Jing Pu et al. VACCINE
- Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells
- (2021) Jose Mateus et al. SCIENCE
- Application of quantitative systems pharmacology to guide the optimal dosing of COVID‐19 vaccines
- (2021) Mario Giorgi et al. CPT-Pharmacometrics & Systems Pharmacology
- Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
- (2021) Einav G. Levin et al. NEW ENGLAND JOURNAL OF MEDICINE
- The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak
- (2020) Hussin A. Rothan et al. JOURNAL OF AUTOIMMUNITY
- Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
- (2020) Feng-Cai Zhu et al. LANCET
- Rapid COVID-19 vaccine development
- (2020) Barney S. Graham SCIENCE
- Immunologic Dose-Response to Adenovirus-Vectored Vaccines in Animals and Humans: A Systematic Review of Dose-Response Studies of Replication Incompetent Adenoviral Vaccine Vectors when Given via an Intramuscular or Subcutaneous Route
- (2020) Sara Afrough et al. Vaccines
- Response Type and Host Species may be Sufficient to Predict Dose-Response Curve Shape for Adenoviral Vector Vaccines
- (2020) John Benest et al. Vaccines
- Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes
- (2020) Shengli Xia et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2020) Feng-Cai Zhu et al. LANCET
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
- (2020) Pedro M Folegatti et al. LANCET
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
- (2020) Lisa A. Jackson et al. NEW ENGLAND JOURNAL OF MEDICINE
- COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
- (2020) Ugur Sahin et al. NATURE
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
- (2020) Evan J. Anderson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
- (2020) Cheryl Keech et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- (2020) Merryn Voysey et al. LANCET
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
- (2020) Maheshi N Ramasamy et al. LANCET
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2020) Yanjun Zhang et al. LANCET INFECTIOUS DISEASES
- Dose finding for new vaccines: The role for immunostimulation/immunodynamic modelling
- (2019) Sophie J. Rhodes et al. JOURNAL OF THEORETICAL BIOLOGY
- Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making
- (2018) Sophie J. Rhodes et al. npj Vaccines
- Exploring the impact of inoculum dose on host immunity and morbidity to inform model-based vaccine design
- (2018) Andreas Handel et al. PLoS Computational Biology
- Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study
- (2016) Jason A. Regules et al. JOURNAL OF INFECTIOUS DISEASES
- The TB vaccine H56+IC31 dose-response curve is peaked not saturating: Data generation for new mathematical modelling methods to inform vaccine dose decisions
- (2016) Sophie J. Rhodes et al. VACCINE
- Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline
- (2014) Ana Carolina Campi-Azevedo et al. BMC INFECTIOUS DISEASES
- Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis
- (2014) Catherine M. T. Sherwin et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development
- (2013) P A Milligan et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- 17DD yellow fever vaccine
- (2013) Reinaldo M. Martins et al. Human Vaccines & Immunotherapeutics
- Pharmacometrics: a quantitative tool of pharmacological research
- (2012) Qing-shan Zheng et al. ACTA PHARMACOLOGICA SINICA
- Immunogenicity of Fractional Doses of Tetravalent A/C/Y/W135 Meningococcal Polysaccharide Vaccine: Results from a Randomized Non-Inferiority Controlled Trial in Uganda
- (2008) Philippe J. Guerin et al. PLoS Neglected Tropical Diseases
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started